BREAKING
In ‘regular contact’ with US on trade deal, says Commerce Secretary Rajesh AgarwalSukhbir Badal attacked in NandedIndia’s total installed power capacity reaches 552 GWKapu leaders push for youth empowerment and entrepreneurshipMaanasa Choudhary launches REDMI Note 17 5GISRO taking steps to tackle space debrisDarpan Furnishings has opened its store in MiyapurCan legislative privileges override free speech?Tata Stocks rebound after Chandra exit shockIf you can’t do it, we will
Business

Morepen Reports Strong Q1 Growth, CDMO Enters Commercial Phase

hellohimachalse@gmail.com 14 Aug 2026 2 hours ago

Morepen Laboratories reported its highest-ever quarterly revenue of ₹575.31 crore in Q1 FY27, up 34% year-on-year. EBITDA surged 207% to ₹87.72 crore, while PAT rose 394% to ₹56.35 crore.

The company’s ₹825-crore CDMO mandate has entered full-scale commercialisation, with ₹58 crore in dispatches completed during the quarter. API business grew 31%, while exports increased 111%.

Medical Devices recorded 19% growth. Morepen also completed its fourth consecutive USFDA inspection with no Form 483 observations, strengthening its global manufacturing and CDMO prospects.

Related News